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Abstract
Introduction: Fibrillary glomerulonephritis (FibGN) is characterized by extracellular deposition of Congo red-
negative microfibrils within the glomerular mesangium and leads to gross proteinuria or nephrotic syndrome. After
diagnosis of FibGN, end-stage renal disease occurs within four years in 50% of patients.
Case presentation: A 36-year-old Caucasian woman with proteinuria and intermittent nephrotic syndrome due to
FibGN intermittently received immunosuppressive therapies, including glucocorticoids, mycophenolate mofetil, and
rituximab, for 10 years. However, disease remission was not achieved and progressive kidney injury developed.
Ultimately, in stage IV of chronic kidney disease (Kidney Disease: Improving Global Outcomes), three cycles of
plasmapheresis of five to seven sessions each were performed every three to four months, reducing steady-state
proteinuria from 7 to less than 1 g/day. Here, plasmapheresis led to a remission of nephrotic syndrome associated
with FibGN.
Conclusions: Plasmapheresis therapy is proposed as a further option for immunosuppressant-refractory FibGN.
Introduction
Fibrillary glomerulonephritis (FibGN), a rare type of glo-
merulopathy, is characterized by extracellular deposition
of Congo red-negative microfibrils (18 to 22 nm) within
the glomerular mesangium and its capillary walls and
leads to gross proteinuria or nephrotic syndrome. After
diagnosis of FibGN, end-stage renal disease occurs within
four years in 50% of patients [1]. Unlike amyloidosis,
cryoglobulinemia, and light-chain glomerulopathy in
patients with multiple myeloma, FibGN is a fibrillary glo-
merulopathy of unknown etiology. Viral infections such
as hepatitis C [2] or human immunodeficiency virus
(HIV) [3] have been suggested to cause FibGN.
There is no generally accepted therapeutic strategy for
FibGN. Early on after diagnosis, FibGN is likely to be ster-
oid-sensitive [4]. For steroid-refractory cases, rituximab [5]
or cyclophosphamide [6] is a therapy alternative. Rituxi-
mab has yielded a partial reduction in nephrotic-range
proteinuria due to FibGN [5], whereas cyclophosphamide
h a sb e e nr e p o r t e dt oh a v ea ne f f e c to nn e p h r o t i c - r a n g e
proteinuria in a case report only [7]. A therapeutic effect
of cyclophosphamide in FibGN was lacking in a retrospec-
tive cohort study [8]. Concerning the use of mycopheno-
late as part of a combination or monotherapy in FibGN,
limited experience exists. In four of 66 published FibGN
cases, mycophenolate was used and a partial remission
was achieved in two of them [9]. To the best of our knowl-
edge, results of plasmapheresis therapy applied in cases of
immunosuppressant-refractory FibGN have not been
reported before. Here, we present a case of immunosup-
pressant-refractory nephrotic syndrome due to FibGN
with remission after repeat plasmapheresis therapy.
Case presentation
A 36-year-old normotensive Caucasian woman was
admitted to our nephrology department one year after a
non-selective glomerular proteinuria of 2.1 g/day, leuko-
cyturia (10/μL), and microhematuria were diagnosed.
Comorbidity included allergic asthma, obesity with a
body mass index of 46.9 kg/m
2, and gastroesophageal
reflux disease. Standard laboratory tests showed normo-
glycemia, glomerular hyperfiltration (creatinine clearance
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(12,600 cells per microliter). Erythrocyte sedimentation
rate was repeatedly found to be elevated (40/43 mm/
hour). Except for a borderline anti-nuclear antibody titer
(1:40) and smooth muscle antibody titer (1:80), the
results of laboratory vasculitis screening were negative.
On serological examination, active HIV or hepatitis (A,
B, or C) infections were ruled out. Serum protein electro-
phoresis showed prominent alpha 1 (9.3%) and alpha 2
(13.2%) fractions and a double peak of the beta fraction.
FibGN was established by typical electron microscopy
findings in the renal biopsy (Figure 1). Upon diagnosis,
an angiotensin-converting enzyme (ACE) inhibitor,
diuretics, and a protein-restricted diet were initiated.
Six months after the diagnosis of FibGN, prednisolone
(60 mg/day tapered off to 10 mg every other day) was
added temporarily. However, proteinuria (2.5 g/day) did
not improve.
Figure 1 Electron microscopy image of a capillary cross-section shows a portion of glomerular basement membrane with
membranous deposits of 15- to 20-nm fibrils (arrows). Fibril density is highest in the vicinity of the capillary lumen and becomes lower
toward the podocyte side of the glomerular basement membrane. Magnification: 12,000×.
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nuria of 6.3 g/day) occurred after a respiratory infection.
Estimated glomerular filtration rate (eGFR) [9] was 108.6
mL/minute per 1.73 m
2. Both leukocyturia and micro-
scopic hematuria deteriorated. Anti-nuclear antibody
titer was 1:160, and leukocytosis (13,300 cells per microli-
ter) persisted. Complement C3 and C4 were within nor-
mal range, and cryoglobulinemia was ruled out. Both
plasma and urinary protein immunofixations were unre-
markable. Abdominal ultrasound, gynecologic, pulmolo-
gic, and urologic exams yielded normal results. Cardiac
workup, including echocardiography and electrocardio-
graphy (ECG), was unrevealing except for an incomplete
right bundle branch block and intraventricular conduc-
tance abnormalities in ECG leads II and aVF. A second
renal biopsy confirmed FibGN. The prednisolone dose
was temporarily increased (60 mg/day for three months
and tapered off to 5 mg every other day) and had to be
discontinued after five more months because of side
effects consistent with iatrogenic Cushing’ss y n d r o m e
(for example, weight gain, glucose intolerance, mood
changes, and typical fat distribution). After discontinua-
tion of steroids, proteinuria remained below 3 g/day for
three years. However, over the course of a total of five
years without immunosuppressive therapy, proteinuria
worsened (4.8 g/day) and eGFR decreased to 64 mL/min-
ute per 1.73 m
2.
Six years after the diagnosis of FibGN, nephrotic syn-
drome recurred (proteinuria of 16.5 g/day) during a
respiratory infection. Both steroid therapy (pulse and
tapering off over the course of four weeks) and mycophe-
nolate mofetil therapy (2 g/day for three months) were
applied. During these therapies, proteinuria leveled off at 2
g/day whereas renal function remained impaired, indica-
tive of chronic kidney disease: KDIGO (Kidney Disease:
Improving Global Outcomes) stage III (eGFR of 50 mL/
minute per 1.73 m
2). Eight years after disease onset, our
patient was readmitted for nephrotic syndrome (protei-
nuria of 20.8 g/day). Albumin/creatinine ratio (ACR) was
3.99 g/g. An aggravated arterial hypertension was
addressed by switching the ACE inhibitor to a combina-
tion of the angiotensin receptor blocker valsartan and the
direct renin antagonist aliskiren. In addition, our patient
received rituximab (375 mg/m
2) weekly for four weeks. In
follow-up exams, proteinuria leveled off at 7 g/day (ACR
of 2.98 g/g) whereas eGFR decreased to 32 mL/minute per
1.73 m
2.
One year later (or nine years after disease onset), our
patient complained of fatigue. The results of ECG and
transthoracic echocardiography remained unchanged,
thereby rendering a cardiac involvement [10] unlikely.
Given the persisting gross proteinuria of 7 g/day, plasma-
pheresis was chosen as salvage therapy to decrease a puta-
tive plasma factor contributing to FibGN. Three cycles of
five to seven plasmapheresis sessions each were performed
during three hospital stays within nine months. During
each session, 3 L of plasma or 71% of estimated plasma
volume was replaced by a 5% human albumin solution.
The treatment was well tolerated. Coagulation tests and
immunoglobulin G checks were performed regularly. After
the first cycle, proteinuria decreased from 7 to 2.2 g/day.
After the second one, proteinuria decreased to 1.2 g/day.
Finally, after the third cycle, proteinuria was below 1 g/day,
indicating that nephrotic syndrome was in remission
(Figure 2). Likewise, ACR decreased from 3.3 g/g before
the onset of plasmapheresis therapy to less than 0.2 g/g
after three cycles of plasmapheresis. Renal function
remained impaired (eGFR of 23 mL/minute per 1.73 m
2)
once steady state was reached. Leukocyturia decreased
from 140 to 7/μL and hematuria improved from 666 to 24
erythrocytes/μL after three cycles of plasmapheresis.
To maintain nephrotic syndrome remission, plasma-
pheresis sessions were scheduled to be performed every
three months. In the maintenance phase, two intermittent
plasmapheresis sessions were actually performed. How-
ever, the last one had to be interrupted after 45 minutes
because of an allergic reaction to albumin in the exchange
fluid. Thus, allergy prophylaxis will be considered in
upcoming plasmapheresis sessions guided by proteinuria.
Ten months after induction plasmapheresis therapy
(or 10 years after the onset of FibGN), remission of
nephrotic syndrome prevailed. Residual proteinuria (0.2
g/day) and creatinine clearance (31.7 mL/minute,
KDIGO stage III) remained stable. Figure 3 displays the
course of serum creatinine and serum albumin. Follow-
ing onset of plasmapheresis, our patient made a consid-
erable recoveryin terms of quality of life, she resumed a
part-time employment.
Discussion
In this case of immunosuppressant-resistant nephrotic
syndrome due to FibGN, plasmapheresis therapy was
chosen as induction (three cycles or 18 sessions in total)
and maintenance therapy, leading to a remission of
nephrotic syndrome in terms of proteinuria reduction to
less than 1 g/day. The already chronically impaired renal
function remained stable. Hypothetically, respiratory
infections triggered nephrotic syndrome episodes in this
patient with FibGN. Before plasmapheresis therapy,
FibGN-associated gross proteinuria or nephrotic syn-
drome was intermittently treated with glucocorticoids,
mycophenolate mofetil, and rituximab in an escalating
fashion over the course of 10 years. Glucocorticoids
were not tolerated by our patient. Alternative immuno-
suppressive therapies only partially improved episodes of
acutely worsened nephrotic syndrome. Long-term suc-
cess has not been achieved. Finally, nephrotic-range pro-
teinuria prevailed and renal function worsened.
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drome-complicated FibGN [9] and toxicity concerns in
long-term use, the FibGN presented here was not trea-
ted with cyclophosphamide. Nonetheless, we consider
this FibGN case to be immunosuppressant-refractory.
Given the prospect of progressive kidney failure, plasma-
pheresis therapy was chosen as an individual experimen-
tal therapy.
Here, evidence arises in favor of plasmapheresis ther-
apy in FibGN. Although a previous review [11] showed
no therapeutic effect of plasmapheresis in three patients
with nephrotic syndrome due to immunotactoid glomer-
ulonephropathy, our case of FibGN showed that protei-
nuria decreased after the initial plasmapheresis cycles.
Considering this observation, we propose plasmapheresis
therapy as a possible rescue therapy for nephrotic syn-
drome in FibGN. Under plasmapheresis maintenance
therapy (two sessions in 10 months), glomerular filtra-
tion rate did not deteriorate during follow-up. Most
importantly, plasmapheresis-induced remission of
nephrotic syndrome improved the quality of life in this
patient with FibGN.
It is unlikely that short-term removal of soluble
plasma constituents will sustainably alter fibril deposi-
tion. The removal of potentially aggravating factors may,
however, preserve podocyte function and thereby lower
the proteinuria. In addition, intermittent plasmapheresis
sessions may be an effective maintenance therapy given
the limitation of the short observation period of six
months. Whether this finding extends to other patients
with FibGN remains unclear. The good initial response
to plasmapheresis seen in our patient stirs interest for
further research on this topic. Larger register studies
summarizing different treatment approaches in FibGN
are desirable as a prerequisite for clinical randomized
trials.
Conclusion
Immunosuppressant-resistant nephrotic syndrome due
to FibGN may respond favorably to plamapharesis
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Figure 2 Proteinuria over time in a case of fibrillary glomerulonephritis (FibGN). Proteinuria (in grams per day) and albumin/creatinine
ratio (in grams of albumin in urine per grams of creatinine in urine) are displayed over time (in months) since the diagnosis of FibGN.
Therapeutic interventions are specified below.
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including clinical randomized trials are needed.
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